TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Consensus Rating of “Hold” by Brokerages

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) have been assigned a consensus rating of “Hold” from the six ratings firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $6.00.

A number of equities research analysts have recently issued reports on the company. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 target price on shares of TScan Therapeutics in a research note on Tuesday, June 23rd. Wall Street Zen lowered TScan Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of TScan Therapeutics in a research note on Tuesday, April 21st. Finally, Wedbush reiterated an “outperform” rating and issued a $5.00 target price on shares of TScan Therapeutics in a research note on Tuesday, June 23rd.

TScan Therapeutics Stock Performance

Shares of NASDAQ:TCRX opened at $0.97 on Wednesday. The firm has a market capitalization of $63.31 million, a PE ratio of -1.01 and a beta of 1.03. The company has a debt-to-equity ratio of 0.34, a current ratio of 6.65 and a quick ratio of 6.65. The business has a 50-day moving average of $1.06 and a two-hundred day moving average of $1.05. TScan Therapeutics has a 12 month low of $0.83 and a 12 month high of $2.57.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.22) EPS for the quarter, hitting the consensus estimate of ($0.22). TScan Therapeutics had a negative return on equity of 91.94% and a negative net margin of 1,360.61%.The company had revenue of $0.98 million during the quarter, compared to analyst estimates of $2.50 million. As a group, research analysts forecast that TScan Therapeutics will post -1.11 earnings per share for the current year.

Institutional Investors Weigh In On TScan Therapeutics

Large investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. boosted its holdings in TScan Therapeutics by 6.0% in the first quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company’s stock valued at $235,000 after purchasing an additional 9,676 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of TScan Therapeutics by 8.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 287,743 shares of the company’s stock valued at $417,000 after buying an additional 22,642 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of TScan Therapeutics during the 2nd quarter valued at approximately $78,000. Qube Research & Technologies Ltd acquired a new stake in shares of TScan Therapeutics during the second quarter worth approximately $99,000. Finally, Jane Street Group LLC acquired a new stake in shares of TScan Therapeutics during the second quarter worth approximately $309,000. Institutional investors and hedge funds own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.